Achilles Therapeutics plc - Rasio nilai perusahaan marang dodolan ACHL

Achilles Therapeutics (ACHL) relies on the potential of the PELEUS platform and bioprinting patents. This GURU.Markets terminal chart displays the current EV/Sales ratio, where the value describes the current level. The asset is shielded from macroeconomic volatility by a sovereign development cycle, although the high cost of scientific research and stringent regulatory oversight create significant barriers to rapid business scaling.
Rincian metrik keuangan lan pasar Achilles Therapeutics plc (ACHL)

A conservative investor assesses the fundamental stability of Achilles Therapeutics (ACHL) by comparing market capitalization with net debt and sales volume. Analyzing the enterprise value-to-revenue ratio helps determine the extent of the premium paid for potential in the untapped personalized immunotherapy segment, where high chart volatility signals a market reassessment of future revenues from clinical centers.